Details

Autor(en) / Beteiligte

• Yu, Yongfeng
• Guo, Qisen
• Zhang, Yongchang
• Fang, Jian
• Zhong, Diansheng
• Liu, Baogang
• Pan, Pinhua
• Lv, Dongqing
• Wu, Lin
• Zhao, Yanqiu
• Li, Juan
• Liu, Zhihua
• Liu, Chunling
• Su, Haichuan
• Fan, Yun
• Zhang, Tongmei
• Liu, Anwen
• Jin, Bo
• Wang, Ye
• Zhou, Jianying
• Zhang, Zhihong
• Ran, Fengming
• Song, Xia
• Shi, Michael
• Su, Weiguo
• Lu, Shun
• Wang, Mengzhao
• Zhang, Xiaodong
• Ma, Rui
• Song, Zizheng
• Li, Xingya
• Cheng, Ying
• Wang, Changli
• Han, Liang
• Shi, Jianhua
• Yu, Zhuang
• Chen, Yuan
• Huang, Jianan
• Min, Xuhong
• Wang, Limin
• Lu, Kaihua
• Yang, Minglei
• Wang, Pingli
• Dong, Xiaorong
• Yu, Guohua
• Wang, Buhai
• Chang, Jianhua
• Duan, Jianchun
• Cang, Shundong
• Song, Quanyi
• Yu, Jie
• Fan, Songhua
• Wang, Linfang
• Ren, Yongxin
• Luo, Xian

Titel

Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study

Ist Teil von

• The lancet respiratory medicine, 2024-09

Ort / Verlag

England: Elsevier Ltd

Erscheinungsjahr

2024

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Savolitinib has been approved in China for advanced or metastatic non-small-cell lung cancer (NSCLC) with MET exon 14 (METex14) skipping alterations in previously treated patients and those unable to receive platinum-based chemotherapy. We report results from a treatment-naive cohort of a phase 3b study that was designed to evaluate the efficacy and safety of savolitinib in locally advanced or metastatic METex14-mutated NSCLC. This single-arm, multicohort, multicentre, open-label, phase 3b study was done at 48 hospitals in China in adult (≥18 years) patients with locally advanced or metastatic METex14-mutated NSCLC who had not received previous systemic antitumour therapy. Patients with a bodyweight of 50 kg or more and those with a bodyweight of less than 50 kg received savolitinib once daily at 600 mg or 400 mg, respectively, in 21-day cycles. The primary endpoint was objective response rate assessed by independent review committee (IRC) per Response Evaluation Criteria in Solid Tumours, version 1.1. The full analysis set comprised all patients who received at least one dose of study medication, which was used to assess the efficacy endpoints and baseline and safety data. This study is registered with ClinicalTrials.gov (NCT04923945) and is closed to accrual. Between Aug 31, 2021, and Oct 20, 2023, 125 treatment-naive patients were assessed for eligibility, of whom 87 were enrolled and received savolitinib. The median age of patients was 70·0 years (IQR 65·2–75·8) and 51 (59%) of 87 patients were male and 36 (41%) were female. In the full analysis set, the IRC-assessed objective response rate was 62% (95% CI 51–72) and the investigator-assessed objective response rate was 60% (49–70), showing a high concordance rate (84%). Treatment-related adverse events were reported in 85 (98%) of 87 patients, with peripheral oedema (54 [62%]) being the most common. Two of these treatment-related adverse events led to death (cardiac failure n=1, unknown reasons n=1). Savolitinib showed manageable toxicity and promising efficacy in treatment-naive patients with advanced or metastatic METex14-mutated NSCLC. HUTCHMED and AstraZeneca.